Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

BioInvent, Audiocast, Q4'25

By Inderes2/26/2026, 1:00 PM
BioInvent International

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Martin
00:01 - 13:26

Thank you and welcome, everybody to our Year-End Report. Today is February 26th, 2026. And as usual, I will start with the summary. So we had a couple of key events in the fourth quarter. First of all, the two ASH data sets. So with BI-1808, our lead candidate, targeting TNFR2, we saw very strong data in T-cell lymphoma. And we presented that at ASH 2025. And I come back to the data a little bit more in detail later. And then we had another ASH presentation about BI-1206, which is our lead candidate targeting FcγRIIB, in combination with rituximab and Calquence in non-Hodgkin's lymphoma. And that was also presented at ASH 2025. And also a very, very strong data set. I should mention that BI-1808 was monotherapy. Single agent therapy. Then we also started our Phase 2 trial evaluating BI-1206 in combination with pembrolizumab in treatment-naïve, advanced or metastatic non-small cell lung cancer and uveal melanoma. So this is really the first line setting. And this is, as I will explain later, based on data we have seen in patients in later lines of therapy. And that data actually convinced Merck to join us in the first-line setting under a supply and collaboration agreement. And then last but not least, we also got Orphan Drug Designation from EMA for BI-1808. Another very important milestone for the treatment of cutaneous T-cell lymphoma. CTCL. And then we had another couple of events after the end of the period. Number one, obviously, a very promising data set in our ongoing Phase 2 study for BI-1808 with KEYTRUDA for the treatment of recurrent ovarian cancer. And we published that ahead of JP Morgan and I will also discuss that data set a little bit more in detail. And then we had a year-end report, and maybe not everybody is aware about this, but I will highlight it, updated clinical data sets for BI-1808 and pembrolizumab in combination in ovarian cancer, as well as the BI-1206 study for the treatment of Non-Hodgkin Lymphoma. So we have additional patients there. And I will mention it again when we discuss specifically those two data sets. And then also, very happy that we could nominate two new board members. Of course, they still need to be confirmed and elected at the annual general meeting. Number one, Kate Hermans. Very experienced and seasoned business person in the pharma and biotech industry. And then Scott Zinober, who was for roughly 20 years the portfolio manager at Viking. So both two very, very strong US profiles. And we're very happy to welcome them to our board. Then before I go into a little bit more in detail, just to have a quick look at our clinical pipeline, as usual, I always emphasize here. So we have multiple value drivers. As you know, in August, we focused on the two more mature programs, BI-1808 and BI-1206, and BI-1808 is currently running in combination with pembrolizumab in recurrent ovarian cancer. And then we have this very nice data set that is actually continuing to generate good data. And then we have planned a new combination study. So this has not been started yet. A combination with BI-1808, pembrolizumab, and paclitaxel, based on the very interesting data that Merck published at ESMO. And this is actually quite exciting because it could lead to a very interesting development in recurrent ovarian cancer. Then, obviously, as you already know. Cutaneous T-cell lymphoma. Let's briefly go over the single-agent data that we presented at ASH. And then we are currently running this also in combination with pembrolizumab, although we already have very strong single agent data in cutaneous T-cell lymphoma of BI-1808, we still want to see how it looks in combination with pembrolizumab. And then BI-1206, the triplet targeting non-Hodgkin’s Lymphoma, specifically follicular lymphoma, mantle cell lymphoma, and marginal zone lymphoma. And there we also have an update. The data set is maturing further and basically confirming the trend, as we also see in the data set in ovarian cancer in combination with pembrolizumab. So that is really very, very encouraging. As already mentioned on the previous slide. So we kicked off first-line combination with pembrolizumab. 1206 in non-small cell lung cancer and uveal melanoma. And there we will see the first readout already during the second half of this year. But I will come back to the milestones this year and also an outlook into 2027. Later, at the end of the presentation, I just want to mention that we see complete and partial responses in all clinical programs, which is truly confirming that the two single agents have activity in both liquid and solid cancer, which I find very comforting. And that's what you want to see at this stage, then going a little bit more into detail. So first, our anti-TNF receptor 2 program, BI-1808, in solid tumors, and then the same in T-cell lymphoma. As already mentioned, we have very promising efficacy in ovarian cancer. And that is building on the single agent activity that we have seen in ovarian cancer. But obviously if you want to treat something like recurring ovarian cancer, you have to go into combination. And since we knew preclinically already that we have strong single agent activity, but also very good synergy with pembrolizumab, it was a no brainer. And that's why we did this. And, in addition to the data that we have shown ahead of J.P. Morgan, we have one additional partial response. So, one stable disease has now turned into a partial response, and there is one additional stable disease, bringing the overall response rate to 24% and the disease control rate to 57%. So basically, the data set that we have shown ahead of J.P. Morgan is being confirmed as it matures further into the right direction. So, again, 24% Overall Response Rate, 57% disease control, and 21 evaluable ovarian cancer patients, which I think is very encouraging and is showing the right trend. And also, when we look on the next slide at the spider plot, you can also see how immunotherapy is working. And we have the firm belief that BI-1808 could be potentially the next KEYTRUDA. And you see here two dotted lines. A pink one, which is basically, if you are above this, it is progressive disease. If you are below this, it is stable disease. And then you have a yellow line. A Partial Response is achieved if you then go below this, and you can see how immunotherapy is working. So you have patients at stable disease and then they're there for a while. The immune system works, and then it gets pushed down into partial response. And this is actually very interesting because, when you look at KEYTRUDA alone, it is around 80%, or in combination with our drug, it is 24%. I think this is actually a very interesting and strong data set, and of course, further maturing, then switching to cutaneous T-cell lymphoma and Peripheral T-cell Lymphoma, our T-cell lymphoma data that we presented at ASH 2025. And there we have shown 46% Objective Response Rate and 92% Disease Control Rate in 13 evaluable CTCL patients. Very strong data set. And I should also mention here, both data sets. So the one in Ovarian cancer, as well as the one in T-cell lymphoma, also have a very excellent safety profile. So it's very, very well tolerated, which is important, especially when you think about the combination in ovarian cancer with pembrolizumab, because you are only able to do this in case you have a good safety profile, which we have. But going back to T-cell lymphoma here on this slide. So, what is important, besides the good safety profile, is that we see immune activation early on, with depletion of regulatory T cells and the influx of CD8 positive T cells into the skin. So we have a clear skin component. And very briefly on the spider plots here, you can also see nice duration already here in this case, the black line. This is basically below that is stable disease. And then you see the dotted line, and below it is partial response. And you can see that we already have a complete response now in Sézary Syndrome which is really continuing for more than a year. So, you can also see that duration is coming into play here, as you could see for the earlier ovarian cancer data set. So it really looks very promising. Then, switching to our other program, our anti-FcγRIIB program BI-1206 in Non-Hodgkin’s Lymphoma, as well as in solid tumors, starting with Non-Hodgkin’s Lymphoma. So this is the combination with rituximab and acalabrutinib. So it's a triplet. And this is a little bit different slide that we have shown so far. So we'll be splitting up now into follicular lymphoma, marginal zone lymphoma and mantle cell lymphoma. We see good responses in both. Dark green is complete. Light green is partial. And, compared with the data set that we showed at the end of last year, we now have additional partial responses and one additional stable disease, maintaining the very good 80% Objective Response Rate and a Disease Control Rate of 100%, which is excellent. And you can see activity in all three subsets. We are focusing more on follicular lymphoma because this is also more interesting for our supply and collaboration partner AstraZeneca, because they don't have follicular lymphoma on the label of Acalabrutinib. Then again, on this spider plot, everything below the dotted line is good because that means it's either a partial response or a complete response. And then you see also quite a number of stable diseases. And you see here also that the data matures. That means you see stable disease. Then it goes into partial response and then eventually into complete response. And we also have very good duration here. And we have some idea about the duration from our study that we did before. That was just 1206 in combination with rituximab. And of course, the patient population we're focusing on consists of patients who no longer respond to anti-CD20 based therapy. And there we have now a couple of patients that actually are in complete response for several years after the end of the study. So then on the solid cancer side for 1206, this is a data set that is from the dose escalation where we were targeting patients. End-of-the-line patients that do not respond anymore to either anti-PD-1 or anti-PD-L1, where we also had some very interesting signals. So we had very interesting complete and partial responses. And based on that, we went back to Merck, and our partner here for the supply collaboration on combination with Keytruda, and we agreed that we should go into Phase 2, a first-line non-small cell lung cancer and melanoma with BI-1206 and pembrolizumab. And this is now ongoing. As I said, the first readout will be during the second half of this year, which is pretty soon. Then I will hand over to Stefan.

Stefan
13:30 - 16:09

You can also see that duration is coming into play here, as was evident for the earlier ovarian cancer data set. Martin, I will present the financial overview for Q4 and the 12-month period, January to December. All amounts are in SEK million unless otherwise mentioned. Net sales were 3 million in Q4 2025, compared to 21.4 million in Q4 2024. That's 18 million lower in Q4 2025. That decrease is related to the production of antibodies for customers being lower in 2025, and net sales for January to December 2025 were 226 million. For the same period in 2024, net sales were 45 million. That's an increase of 182 million. The increase is mainly related to the $20 million payment we received when XOMA Royalty acquired future royalty and milestones interest for Mezagitamab. And before that, we got a $1 million milestone in that collaboration. For production of antibodies for customers was 19 million lower in 2025. Operating costs decreased from 147 million in Q4 2024 to 132 million in Q4 2025. That's a decrease of 15 million. We had quite higher costs in BI-1808, quite lower costs in BI-1607, and lower costs in BI-1206 and BI-1910. And we had somewhat higher personnel costs in Q4 2025 for January to December. The increase of operating costs was 62 million, from 516 million in 2024 to 578 million in 2025. We had quite higher costs in BI-1808 and BI-1206 and quite lower costs in BI-1607, and lower costs for production of antibodies for our customers. Personnel costs in 2025 were significantly higher compared to 2024, and the result for Q4 2025 was -125.8 million, and the result for January to December 2025 was 332.9 million, and liquid funds and current investments at the end of December 2025 amounted to a total of 593 million. And finally, based on ongoing studies, BioInvent International AB is assessed to be financed for the coming 12-month period. Over to you, Martin.

Martin
16:09 - 19:29

Martin, I will present the financial overview for Q4 and the 12-month period, January to December. Stefan. So at the end of the presentation, I want to go over the key catalysts for the remaining part of this year, as well as give you an outlook for 2027. And as you will see, this is actually quite a dense picture here. So we have a lot of interesting news this and next year. So starting with BI-1808 and T-cell lymphoma. So already by mid this year, we'll have first Phase 2a data in combination with pembrolizumab, but also additional monotherapy data since we do dose optimization at the moment. Then for BI-1808 in solid tumors, in the second half of this year, we should have further Phase 2 data in combination with pembrolizumab. And as you could see already here. So the data is maturing in the right direction. So that should also be a very interesting milestone to look forward to; then, switching to BI-1206 (targeting FcγRIIB), Objective Response Rate data will be available mid-year already. The additional Phase 2a data in combination with rituximab and acalabrutinib. And then, last but not least, BI-1206 in solid tumors, including first-line non-small cell lung cancer and melanoma, will have its first data readout during the second half of this year. Looking ahead to 2027, starting from the top, our TNFR2 platform, BI-1808, in T-cell lymphoma, will complete its Phase 2 dose optimization during the first half. That is the monotherapy, and then during the second half, we could potentially start the pivotal study; then, BI-1808 in solid tumors, during the second half of next year, would potentially have the first Phase 2a data for the triplet in combination with pembrolizumab and paclitaxel. And this is actually quite interesting because in case we really see a nice uplift there, and maybe we can later discuss it during the Q&A in more detail. This could also then lead, immediately, of course, data-driven, to a pivotal study. So very, very interesting. Program to follow then. FcγRIIB. BI-1206 in non-Hodgkin’s Lymphoma, so during the first half of 2027, we potentially could start the pivotal triplet study. And then in the solid cancers, first-line non-small cell lung cancer and uveal melanoma, during the first half of 2027, we complete the Phase 2 data and could potentially start during the second half Phase 2b of BI-1206 plus pembrolizumab in non-small cell lung cancer. So, as I mentioned, a very dense news flow, very interesting milestones. And that should be something really looking forward to. And I think I will end here, my presentation, and happy to take questions. The additional Phase 2a data in combination with rituximab and acalabrutinib.

Operator
19:33 - 19:51

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Richard Romanus from Redeye. And I will end my presentation here and am happy to take questions.

Richard Romanus
19:54 - 20:13

Good afternoon. Why not start off on the last slide? When do you think it would make sense to take in a partner to conduct any of these studies? And I guess these would be studies extending through 2027.

Martin
20:15 - 21:16

Yeah. So basically, what I can say to that is that we are in interesting discussions; as you know, we have a very active approach in business development partnering anyway. And we are in discussions with some company for some time. Obviously we have AstraZeneca and Merck already at the table in a way through those supply and collaboration agreements, and they follow the programs very closely. And I think we might already see some activity around partnering, potential partnering, dealmaking. During the second half of this year. And of course, you can never promise; it's always dependent on the data, the market environment, etc. But we will be keen to partner one or the other with, hopefully, large pharma companies such as Merck and AstraZeneca.

Richard Romanus
21:19 - 21:33

Right. Could you just clarify more in detail exactly what you need to accomplish with BI-1206 in non-Hodgkin’s Lymphoma to make the triplet ready for a pivotal trial.

Martin
21:35 - 22:21

Yeah. So basically, we will have, as I already mentioned, the 30 patients in the current ongoing study. That's enough. And then we can discuss with the regulators and start preparing for potential pivotal study. That's why I think that will take the rest of the year once we have the data by mid this year. And then, we could start that potentially next year. But also to mention it here. So our main focus currently from a strategic perspective is more on the solid cancer side because that is a much stronger value driver. But we are committed to get the T-cell lymphoma as well as the non-Hodgkin’s Lymphoma that you are talking about, ready for potential pivotal study.

Richard Romanus
22:24 - 22:30

The last question. What funding options do you have for 2027?

Martin
22:32 - 22:54

So obviously we will look at everything all the time. Number one, we're looking at partnering. And number two, of course there's always financing options because I think if you have good data, as we have, you have always both possibilities. But we have a strong focus on partnering. Okay.

Richard Romanus
22:55 - 22:56

Right. Thanks for taking my questions.

Martin
22:57 - 22:58

Thank you Richard.

Operator
23:01 - 23:06

The next question comes from Sebastiaan van der Schoot from Kempen. Right.

Chiara Montironi
23:08 - 23:50

Hello. Thanks for taking my question. I'm Chiara Montironi on behalf of Sebastian. So, a couple from me, if I may, again, regarding potential partner discussion, could you go over whether BI-1206 (considering its Objective Response Rate) or BI-1808 is one of the more logical options to outlicense. And the second question will be around. Uveal melanoma and first-line non-small cell lung cancer data set for BI-1206. Can you provide some insight into what magnitude of efficacy would give you enough comfort to continue forward with the program? So regarding partnering, we are currently discussing both BI-1808 and BI-1206.

Martin
23:51 - 24:39

Yeah, thank you very much for those questions. And very nice to meet you. So regarding partnering, we are currently discussing both 1808 and 1206. So we have discussions around both programs. And that's also what you should do as a biotech company because you can't be picky. You have to see what opportunity turns up and then you go from there. My dream scenario would be, though, that we keep BI-1808 a little bit longer and partner BI-1206 first, but as I said, we have discussions around both at the moment. Then, regarding the data set of BI-1206 in first-line non-small cell lung cancer, I think what we would like to see as a target is a 60% ORR, and I think then we will be in good shape.

Chiara Montironi
24:42 - 24:43

Can you provide some insight into what magnitude of efficacy would give you enough comfort to continue forward with the program? So regarding partnering, we are currently discussing both 1808 and 1206.

Operator
24:48 - 24:53

The next question comes from Arvid Nicotra from NBI Carnegie. Please go ahead.

Richard Romanus
24:56 - 25:37

Good afternoon and thanks for taking my questions. I came a bit late here, so sorry if the questions have already been answered, but the first one on BI-1206. So really good to see the breakdown of responses by subtype and Non-Hodgkin’s Lymphoma. So, on the back of this analysis, I just wanted to ask if follicular lymphoma is the indication that makes most sense to pursue for the registration-directed trial, and then, secondly, regarding the non-small cell lung cancer data targeted for the second half of the year, which will provide an important new signal, how should we think about expectations here? What would mark a strong outcome in your view? Yeah, thanks.

Martin
25:38 - 27:21

Thank you for your questions. Maybe I'll start with the last one first because there was a little bit of an overlap regarding that already. So, our expectation is to see an ORR. So that's BI-1206 in combination with pembrolizumab in first-line non-small cell lung cancer, with an Objective Response Rate of 60%. I think if you see that, it will be a strong signal. And in that sense, also, it's a very good clinical trial because we really put it to the test. And if we see this kind of response, I think we are very happy. And I think that would also be something that is super interesting for Merck: the Objective Response Rate should be super interesting for Merck. Then regarding BI-1206, in Non-Hodgkin’s Lymphoma. Yes, I think the activity is in all three, and we had a stronger focus on follicular lymphoma, and I think I mentioned it during the presentation. Maybe you didn't hear this. This is a little bit driven by our supply and collaboration partner, AstraZeneca, because Acalabrutinib doesn't have follicular lymphoma on the label. And since we think that might be a potential partnering possibility, we were focusing on follicular lymphoma a little bit more than on the other two. And what we were trying to do is have a focus on follicular lymphoma at the same time point, also showing that it works for marginal zone as well as mantle cell lymphoma, which I think we clearly did. And of course, also for the audience here, when you look at non-Hodgkin lymphoma, the largest, by far, population is follicular lymphoma. I think also from a commercial perspective, it makes a lot of sense.

Richard Romanus
27:25 - 27:28

Perfect. Thank you Martin. I'll jump back in the queue.

Martin
27:28 - 27:29

This is a little bit driven by our supply and collaboration partner, AstraZeneca, because Acalabrutinib doesn't have follicular lymphoma on the label.

Operator
27:34 - 27:39

The next question comes from Dan, actually, from Pareto Securities. Please go ahead.

Dan
27:41 - 28:46

Hi Martin, and congrats on the progress. Now with potentially two pivotal programs next year, and I think there's been a lot of discussion about partnering. Both drugs work in multiple settings. So I'm thinking of it like how are you going into these negotiations if you can share a bit more. Because follicular lymphoma, for instance, as with any approved immuno oncology drug, they never stay approved in only one indication. So it's kind of a mechanism, proof of concept that you have. Are you marketing this specifically or do you see interest from. That from the pharma side, to basically not just do a deal on the indication, but. Broader, on the drug or on the mechanism. And then, how do you approach that for both drugs, namely BI-1808 and BI-1206, and if you have gotten this kind of interest from pharma, has it been very indication-specific? This is a little bit driven by our supply and collaboration partner, AstraZeneca, because Acalabrutinib doesn't have follicular lymphoma on the label.

Martin
28:47 - 32:42

Yeah. This is a little bit driven by our supply and collaboration partner, AstraZeneca, because Acalabrutinib doesn't have follicular lymphoma on the label. Dan. So, I think in general, you can say, and that's what you see also here on this slide. So, 1808 is our TNFR2 platform and 1206 our FcγRIIB platform because both mechanisms, as you say, are broad. And of course, what you do in early clinical development, you try to find a signal that you can follow in order to generate some more comprehensive data sets. And that's what we're doing. And especially as a small company, you have to be very prudent because you can't go too broad at the beginning. But just to go through maybe step by step. So when you look at 1808 first, maybe you can clearly see that we already have established a very broad efficacy range. So remember the single-agent activity in GIST, in ovarian cancer, but also in lung cancer. And now the strong data set in combination with pembrolizumab. At the same time, we also see strong single agent activity in T-cell lymphoma. So they can already see the broad potential application range for that compound. And talking about 1808 first maybe. So, yes, the discussions that we have are, of course, initially indication-driven, because wherever you have the first more comprehensive data set, that's what drives it. And of course, that we had with T-cell lymphoma. But now since we have the ovarian cancer data sets since early this year, we also have interesting discussions around ovarian cancer, obviously. So, absolutely broad. And the same is true for BI-1206. So we have this in non-Hodgkin’s Lymphoma and of course, the study that we run is very targeted towards AstraZeneca in a way. So we'll see how that works out. And we will know that probably already quite soon. But then you have the solid tumor side where we work in combination with pembrolizumab and especially 1206 is quite interesting because there we have a supply and collaboration agreement with AstraZeneca regarding acalabrutinib for non-Hodgkin’s Lymphoma. And of course, an additional supply and collaboration agreement exists with Merck for solid cancers, applicable to both compounds. I would also say, starting again with 1808, if we continue to see what we are seeing, then it will not only be interesting for ovarian cancer but also for other cancers, like perhaps triple-negative breast cancer, for example, and possibly other solid cancers. So I think very broad application potential. But we go one step at a time. So current focus clearly on ovarian cancer, which is already a quite interesting market. And the same is true for 1206 in solid tumors. If it should work, as we hope, achieving around 60% efficacy in first-line non-small cell lung cancer, then there's no reason why it should not work with other solid cancer indications in combination with pembrolizumab. First line. So both have a platform. It's a platform with potential and application. And that's how also our discussions are driven. So obviously they start with the first data sets. And once you have the other data sets, the application potential continues to grow. And of course, what we are trying to do is to see that we also reach that stage. So with BI-1808, we have that now with the ovarian cancer data. And there will be further Ovarian cancer data already during the second half of this year. And then for BI-1206, with the second half of this year, the first readout for the combination with pembrolizumab in first-line non-small cell lung cancer. It will also initiate these types of discussions.

Dan
32:45 - 33:12

And there will be further Ovarian cancer data already during the second half of this year. And there will be further Ovarian cancer data already during the second half of this year. Just a follow-up, if I may. And maybe you cannot answer this, but can you share if you see a willingness from pharma to value these assets broadly? Is there interest in broader patents beyond composition of matter or broader preclinical data that you have? Do you see signs that are really indicating that they are really interested in the platform? Or maybe you cannot share that with us.

Martin
33:12 - 34:17

Well, I can talk about it, of course, in general ways. And I can refer a little bit to the discussions that we had during J.P. Morgan. J.P. Morgan, who had a discussion, which was really interesting, where exactly what you were describing was the case. They were obviously super intrigued by the T-cell lymphoma data, but then also highlighted the very beautiful Ovarian cancer data, which is also, I think, interesting for the audience. We also just uploaded a publication that is really describing in detail how it works. And I think a lot of partners or potential partners really value the depth that we have regarding the science. So we can really and have described in this publication how BI-1808 works in detail. And I think the clinical data, in hand with the pre-clinical, science, and mechanistic data, is important to drive good and fruitful partnering discussions. And we have that.

Dan
34:20 - 34:21

Cool. And there will be further ovarian cancer data already during the second half of this year.

Martin
34:22 - 34:22

Thank you Dan.

Operator
34:25 - 34:29

The next question comes from Oscar Hafen lamb from Stifel. Please go ahead.

Oscar Hafen Lamb
34:32 - 34:59

Hi. Thank you for taking my questions. My first one will be on BI-1808 in Cutaneous T-cell lymphoma. With data expected in combination with pembrolizumab in mid-2026 and potential start of a pivotal trial by next year. I was just wondering what will decide whether to use the monotherapy or combination with pembrolizumab in the pivotal trial. Will it be purely based on efficacy, or will safety be considered as well? Just curious to hear your thoughts on that.

Martin
35:00 - 36:41

So basically, just as a background also to the audience. So currently, and coming back to the milestone that you were just referring to. It will not be only the pembrolizumab data. There will also be additional pembrolizumab combination data, but also additional mono data. Because what we're currently doing is we are running it in combination with pembrolizumab. But we are also already performing dose optimization in monotherapy with the single agent. Basically. And a key driver, of course, will be a significantly better Objective Response Rate. And of course, at the end, it's a little bit early for that. But duration, of course, is also important. And then of course, also safety. Yeah. So, we did some analysis with some external help, and the expectation would really be that if you combine it with pembrolizumab, you see an uptick in efficacy. And of course, you don't want to have safety problems because at the moment, safety is really, really good. And I think that is also a very important aspect of our monotherapy data that we have so far. Since we have such good safety, we could also go into earlier lines of the disease. Since we have no toxicity. And I think that is also quite important. And of course, this would also widen the patient population that you might be able to treat. So, we really want to see an uptick. And the reason why we do it is just to see whether we can have a better efficacy. I think the efficacy that we already have as a monotherapy is good, is exceptional, especially in combination with the safety that we see.

Oscar Hafen Lamb
36:45 - 36:53

Thank you. Just to follow up on that, how many patients do you aim to enroll in cutaneous T-cell lymphoma before the end of Phase 2 meeting with the FDA?

Martin
36:54 - 37:17

So it will be the full data set. I don't have that at the moment in front of me. I think what we have shown so far was 15 plus patients. It will be roughly double that number. And I think now I'm talking about the monotherapy data. And then, for the pembrolizumab data, it's approximately 15 patients. In combination with pembrolizumab.

Oscar Hafen Lamb
37:19 - 37:42

And I think for the now I'm talking about the monotherapy data. Just one last question for me. Still in BI-1808, but this time in Ovarian cancer, is the decision to add paclitaxel to the combination of BI-1808 and KEYTRUDA a result of some conversations with Merck? I mean, maybe they've hinted to what they want to see in the data. And then maybe as a follow up on that, how many patients will you recruit for that arm?

Martin
37:43 - 39:19

Yeah. So, basically, that thought was triggered much, much earlier. It was already part of our protocol when we started the doublet. We first just wanted to see how it works in combination with pembrolizumab. And this we know now. So, it's 18.8%. Compared to 24% in the combination. And since we were following the field quite closely, we had already in the protocol that we could go with a triplet. We have already done some preclinical work, and we know BI-1808 also works very well with paclitaxel. So, once we saw the data published by Merck, and the only thing missing, we were actually already quite convinced by that. But the only thing that was missing for us to really plan this more seriously was the approval of pembrolizumab and paclitaxel. And we expect a favorable safety profile, at least no additional safety issues compared to Keytruda combined with paclitaxel. Plus, of course, a very nice uptick in overall response rate. And here again, I don't have the patient numbers in front of me, but I think it was around 30 patients that we want to do in the triplet. Maybe a little bit more, at least the amount of patients that will be needed in order to have, as a next step, potential pivotal study.

Oscar Hafen Lamb
39:23 - 39:24

Still regarding BI-1808, but this time in ovarian cancer, is the decision to add paclitaxel to the combination of BI-1808 and KEYTRUDA made as a result of some conversations with Merck? Thank you. Very clear.

Martin
39:26 - 39:27

Still in 1808, but this time in Ovarian cancer, is the decision to add paclitaxel to the combo of 1808 and KEYTRUDA based on some conversations with Merck? Oscar.

Operator
39:30 - 39:46

As a reminder, if you wish to ask a question, please dial pound key on your telephone keypad. There are no more questions at this time. So I hand the conference back to the speakers for any closing comments.

Martin
39:48 - 40:56

Thanks, everybody, for participating in our call. Also, the very good questions. I think that discussion around those questions helped a lot to really demonstrate and show that we are at a very important and interesting time of the company. The slide of the key expected clinical milestones is still up on this presentation. So I think, with that, you can clearly see very dense news flow, as I already mentioned. And each of those programs can drive very interesting value development for the company. So stay tuned. And already by mid this year there should be more. And then, we will see where we land. But I'm very optimistic for the company, and I think from my perspective, the most important thing is the data. And the data is good. And we knew that already, but it's also maturing in the right direction. So I think that gives me a lot of hope and confidence. Thank you very much.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…